Testosterone Science

Cancer

FDA Reverses Course on Testosterone, Igniting a New Era for Men’s Health

Specific Claim Evaluated

The FDA has proposed removing the limitation of use for age-related low testosterone and narrowing the prostate cancer contraindication to metastatic disease, after removing the cardiovascular boxed warning language in February 2025.

Primary Research Supporting or Contradicting the Claim

In February 2025, the FDA announced class-wide labeling changes that removed boxed warning language on adverse cardiovascular outcomes and added blood pressure warnings (U.S. Food and Drug Administration, 2025). In June 2026, the FDA requested further prescribing information updates (U.S. Food and Drug Administration, 2026b). TRAVERSE showed noninferiority for major adverse cardiac events (Lincoff et al., 2023).

Corrected Evidence-Based Interpretation

The article is correct. The June 2026 changes were requested, not final, and the TRAVERSE result applies to men with confirmed hypogonadism.

Rationale for Grade

Despite a promotional headline, the body describes the June 2026 action as a proposal, dates the earlier boxed warning change correctly and includes expert comment that diagnosis must rest on symptoms and validated laboratory testing. The regulatory and trial statements match the primary sources.

References

  1. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
    Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"
  2. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety and availability. February 28, 2025.
    Supporting excerpt: "removing language from the Boxed Warning related to an increased risk"
  3. U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
    Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.